Blog

Jayastu Senapati: Check out our poster on display at ASH23

Jayastu Senapati/X

Dec 15, 2023, 06:27

Jayastu Senapati: Check out our poster on display at ASH23

Jayastu Senapati, Assistant Professor at the Department of Leukemia at MD Anderson Cancer Center, shared on X/Twitter:

“Check out our poster on display today at the American Society of Hematology (ASH23).
-High-risk cytogenetics (HG-CTG) loses prognostic impact with inotuzumab ozogamicin (InO) and blinatumomab (Blina) added to frontline HyperCVAD chemotherapy in newly diagnosed patients with Philadelphia negative B-cell Acute Lymphoblastic Leukemia.
-Further analysis underway.”

Source: Jayastu Senapati/X

Acute Lymphoblastic Leukemia American Society of Hematology ASH23 blinatumomab cancer High-risk cytogenetics (HG-CTG) HyperCVAD inotuzumab ozogamicin Jayastu Senapati MD Anderson Cancer Center OncoDaily Oncology

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage